Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Three methods tested to model SF-6D health utilities for health states involving comorbidity/co-occurring conditions.

Hanmer J, Vanness D, Gangnon R, Palta M, Fryback DG.

J Clin Epidemiol. 2010 Mar;63(3):331-41. doi: 10.1016/j.jclinepi.2009.06.013. Epub 2009 Nov 6.

2.

Estimating health state utility values for comorbid health conditions using SF-6D data.

Ara R, Brazier J.

Value Health. 2011 Jul-Aug;14(5):740-5. doi: 10.1016/j.jval.2010.12.011. Epub 2011 May 31.

3.

The development of a model for translation of the Neck Disability Index to utility scores for cost-utility analysis in cervical disorders.

Richardson SS, Berven S.

Spine J. 2012 Jan;12(1):55-62. doi: 10.1016/j.spinee.2011.12.002. Epub 2011 Dec 29.

PMID:
22209244
4.

Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.

Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D.

Value Health. 2009 Nov-Dec;12(8):1151-7. doi: 10.1111/j.1524-4733.2009.00569.x. Epub 2009 Jun 25.

5.

Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.

Hawton A, Green C, Telford C, Zajicek J, Wright D.

Value Health. 2012 Dec;15(8):1084-91. doi: 10.1016/j.jval.2012.07.007. Epub 2012 Nov 4.

6.

Predicting preference-based SF-6D index scores from the SF-8 health survey.

Wang P, Fu AZ, Wee HL, Lee J, Tai ES, Thumboo J, Luo N.

Qual Life Res. 2013 Sep;22(7):1675-83. doi: 10.1007/s11136-012-0284-6. Epub 2012 Oct 10.

PMID:
23054496
8.

Predicting EQ-5D-US and SF-6D societal health state values from the Osteoporosis Assessment Questionnaire.

McDonough CM, Grove MR, Elledge AD, Tosteson AN.

Osteoporos Int. 2012 Feb;23(2):723-32. doi: 10.1007/s00198-011-1619-9. Epub 2011 Apr 12.

9.

Mapping between the Roland Morris Questionnaire and generic preference-based measures.

Khan KA, Madan J, Petrou S, Lamb SE.

Value Health. 2014 Sep;17(6):686-95. doi: 10.1016/j.jval.2014.07.001.

10.

A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.

Salaffi F, Carotti M, Ciapetti A, Gasparini S, Grassi W.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):661-71. Epub 2011 Aug 31.

PMID:
21813061
11.

Associations of cancer and other chronic medical conditions with SF-6D preference-based scores in Medicare beneficiaries.

Hays RD, Reeve BB, Smith AW, Clauser SB.

Qual Life Res. 2014 Mar;23(2):385-91. doi: 10.1007/s11136-013-0503-9. Epub 2013 Aug 29.

12.

Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.

Tramontano AC, Schrag DL, Malin JK, Miller MC, Weeks JC, Swan JS, McMahon PM.

Med Decis Making. 2015 Apr;35(3):371-87. doi: 10.1177/0272989X15570364. Epub 2015 Feb 10.

PMID:
25670839
13.
14.

Quality of life in cochlear implantees: comparing utility values obtained through the Medical Outcome Study Short-Form Survey-6D and the Health Utility Index Mark 3.

Arnoldner C, Lin VY, Bresler R, Kaider A, Kuthubutheen J, Shipp D, Chen JM.

Laryngoscope. 2014 Nov;124(11):2586-90. doi: 10.1002/lary.24648. Epub 2014 Aug 11.

PMID:
24536018
15.
16.

SF-6D utility index as measure of minimally important difference in health status change.

Gandhi PK, Ried LD, Bibbey A, Huang IC.

J Am Pharm Assoc (2003). 2012 Jan-Feb;52(1):34-42. doi: 10.1331/JAPhA.2012.10114.

PMID:
22257614
17.

Predicting an SF-6D preference-based score using MCS and PCS scores from the SF-12 or SF-36.

Hanmer J.

Value Health. 2009 Sep;12(6):958-66. doi: 10.1111/j.1524-4733.2009.00535.x. Epub 2009 Mar 24.

18.

Mapping CushingQoL scores onto SF-6D utility values in patients with Cushing's syndrome.

Roset M, Badia X, Forsythe A, Webb SM.

Patient. 2013;6(2):103-11. doi: 10.1007/s40271-013-0010-7.

19.

Examining the relationship between health-related quality of life and increasing numbers of diagnoses.

Barra M, Augestad LA, Whitehurst DG, Rand-Hendriksen K.

Qual Life Res. 2015 Dec;24(12):2823-32. doi: 10.1007/s11136-015-1026-3. Epub 2015 Jun 12.

20.

Mapping the Functional Assessment of Cancer Therapy-general or -Colorectal to SF-6D in Chinese patients with colorectal neoplasm.

Wong CK, Lam CL, Rowen D, McGhee SM, Ma KP, Law WL, Poon JT, Chan P, Kwong DL, Tsang J.

Value Health. 2012 May;15(3):495-503. doi: 10.1016/j.jval.2011.12.009. Epub 2012 Feb 17.

Supplemental Content

Support Center